What Happened?

Shares of healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) jumped 41.1% in the afternoon session after the company reported decent first quarter 2025 results which significantly beat EPS and EBITDA expectations, though misses on full-year EPS guidance and constant currency revenue. Sales fell 3%, hurt by a sharp drop in COVID-19 and Donor Screening tests, even though core labs and respiratory (excluding COVID) grew at a solid pace. Zooming out, we think this was a decent quarter featuring some areas of strength but also some blemishes.

The shares closed the day at $36.41, up 41% from previous close.

Is now the time to buy QuidelOrtho? Access our full analysis report here, it’s free.

What The Market Is Telling Us

QuidelOrtho’s shares are very volatile and have had 23 moves greater than 5% over the last year. But moves this big are rare even for QuidelOrtho and indicate this news significantly impacted the market’s perception of the business.

QuidelOrtho is down 17.8% since the beginning of the year, and at $37.01 per share, it is trading 22.3% below its 52-week high of $47.61 from January 2025. Investors who bought $1,000 worth of QuidelOrtho’s shares 5 years ago would now be looking at an investment worth $233.35.

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

View Comments